États-Unis · Plateformes & données · MarketBeat

Milestone Pharmaceuticals Q3 Earnings Call Highlights

Publié par MarketBeat · États-Unis il y a 31 min

Image from MarketBeat Media, LLC. · MarketBeat

Résumé détaillé

Milestone Pharmaceuticals (NASDAQ:MIST) plans to cut operating expenses by approximately 30% as it seeks to extend its cash runway while building sales of CARDAMYST and advancing a late-stage clinical trial. The company reported approximately 1,800 CARDAMYST prescriptions in the third quarter of 20

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Milestone Pharmaceuticals Q3 Earnings Call Highlights

Résumé détaillé

À lire aussi

Nvidia’s stock is on a losing streak not seen in 14 years. What comes next?

Careful adjustment of policy is appropriate, says Susan Collins on 50 bps rate hike

Why Is MP Materials Stock Gaining Friday?

Eagle Point Cred earnings beat by $0.12, revenue topped estimates

Chicago Fed's Goolsbee says central bank 'has definitely got work to do' on inflation

Australia B2B Buy Now Pay Later Market and Investment Opportunities Databook - Q2 2026 Update, 45+ KPIs and Forecasts to 2030 | GMV to Reach US$11.52 Billion as Embedded ...

Milestone Pharmaceuticals Q3 Earnings Call Highlights

Résumé détaillé

Partager

À lire aussi

Nvidia’s stock is on a losing streak not seen in 14 years. What comes next?

Careful adjustment of policy is appropriate, says Susan Collins on 50 bps rate hike

Why Is MP Materials Stock Gaining Friday?

Eagle Point Cred earnings beat by $0.12, revenue topped estimates

Chicago Fed's Goolsbee says central bank 'has definitely got work to do' on inflation

Australia B2B Buy Now Pay Later Market and Investment Opportunities Databook - Q2 2026 Update, 45+ KPIs and Forecasts to 2030 | GMV to Reach US$11.52 Billion as Embedded ...